#USA #Mountain View #Turn Biotechnologies #ERA™ Therapy #Bone Marrow

Turn Biotechnologies Advances Stem Cell Treatment with ERA™ Therapy

Introduction

In a groundbreaking move, Turn Biotechnologies announced a significant study focused on its novel ERA™ therapy, aimed at rejuvenating bone marrow. This cutting-edge research is set to evaluate the efficacy of epigenetic reprogramming to enhance the function of bone marrow stem cells, which are critically important for producing blood cells. The study is notably supported by the Methuselah Foundation and holds promise for improving outcomes in stem cell transplantation, particularly for patients dependent on healthy bone marrow function.

Background of the Study

Bone marrow plays a crucial role in the human body by supplying blood cells necessary for combating diseases and regulating inflammation. However, as individuals age, their bone marrow's ability to produce vital immune cells, like T and B cells, declines, leading to increased vulnerability to infections and diseases. This age-related deterioration is often accompanied by genetic alterations, termed clonal hematopoiesis, which can predispose individuals to serious conditions such as leukemia.

Timothy Olson, MD, PhD, the lead investigator from the Children’s Hospital of Philadelphia, articulated the imperative of the study, emphasizing that patients receiving stem cells from younger donors generally experience better clinical outcomes. This improvement is attributed to a more durable correction of underlying blood and immune defects, suggesting that rejuvenating stem cells could enhance the accessibility and effectiveness of bone marrow transplants.

Goals and Methodology

The study will last for one year and aims to measure the efficacy of Turn Biotechnologies' ERA solution by treating blood progenitor cells in mice and transplanting these rejuvenated cells into irradiated mice with the same genetic makeup. Researchers expect that by rejuvenating aged bone marrow stem cells, patients will experience enhanced health outcomes—ranging from improved disease resistance to accelerated wound healing and better oxygen transport capabilities in blood cells.

David Gobel, co-founder and CEO of the Methuselah Foundation, expressed optimism that this innovative study will validate the potential of epigenetic reprogramming to restore youthful cellular function. He believes that findings from this research could also contribute significantly to extending healthy human lifespans.

Implications for the Future

By focusing on the rejuvenation of donor stem cells, the research aims to not only improve transplant success rates but also widen the eligibility for stem cell donations, potentially allowing for older donors who may previously have been excluded. As Turn Biotechnologies progresses into this next phase of research, there is a collective hope that it will transition their scientific findings from theory into practical applications that resonate on a broad scale in the field of regenerative medicine.

Anja Krammer, CEO of Turn Bio, emphasized the significance of this study as it signals a move beyond individual treatments to creating comprehensive solutions for various diseases. She firmly stated that the company has repeatedly demonstrated the potential of ERA treatments to rejuvenate human cells safely, and this study presents an exciting opportunity to bridge the gap between theoretical research and practical solutions.

About Turn Biotechnologies

Turn Bio is a preclinical-stage company dedicated to cellular-level tissue repair and the development of innovative drug delivery systems. Their ERA™ technology, grounded in mRNA, is designed to restore optimal gene expression, combatting the effects of aging in the epigenome. This advancement aims to enable cells to prevent and treat diseases effectively, facilitating tissue regeneration and healing. Turn Bio's research extends to custom therapies targeting dermatological and immunological indications, along with advancements in ophthalmology, osteoarthritis, and muscle health. For more information about their pioneering work, visit turn.bio.

Conclusion

As Turn Biotechnologies embarks on this critical study, the implications for patients relying on stem cell transplants could be profound. By potentially enhancing the efficacy of these life-saving treatments, they aim to usher in a new era of medical advancements focused on rejuvenation and longevity, promising hope for those affected by age-related health issues.